Multiple patterns of MDM-2 deregulation in human leukemias: Implications in leukemogenesis and prognosis

Leukemia and Lymphoma

Volumn 17, Issue 1-2, 1995, Pages 13-18

  Bueso Ramos, Carlos E ^a   Manshouri, Taghi ^a   Haidar, Mohammad A ^a   Huh, Yang O ^a   Keating, Michael J ^b   Albitar, Maher ^a  

^a Division of Laboratory Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gene deregulation; Isoforms leukemia; MDM 2; RT PCR

Indexed keywords

ISOPROTEIN; MESSENGER RNA; POLYCLONAL ANTIBODY; PROTEIN P53;

DOUBLE MINUTE CHROMOSOME; FLOW CYTOMETRY; GENETIC HETEROGENEITY; HUMAN; IMMUNOBLOTTING; LEUKEMIA; LEUKEMOGENESIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION REGULATION, LEUKEMIC; HUMAN; LEUKEMIA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028899276     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199509051698     Document Type: Article

References (35)

1. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway
2. The p53 tumor suppressor gene
3. p53 mutations in human cancers
4. Clinical implications of the p53 tumor-suppressor gene
5. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein
6. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
7. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line
8. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
9. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest
10. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53
11. Mapping of the p53 and mdm-2 interaction domains
12. The p53-MDM-2 autoregulatory feedback loop
13. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene
14. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes
15. MDM2 expression is induced by wild type p53 activity
16. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein
17. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth
18. Amplification of a gene encoding a p53-as-sociated protein in human sarcomas
19. p53 mutation and MDM-2 amplification in human soft tissue sarcomas
20. MDM2 gene amplification in metastatic osteosarcoma
21. The human MDM-2 oncogene is over-expressed in leukemias
22. Amplification and overexpression of the MDM-2 gene in a subset of human malignant gliomas without p53 mutations
23. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes
24. Physical and functional interaction between wild-type p53 and mdm2 proteins
25. Detection of MDM2-proto-oncogene in paraffin embedded human bronchial epithelium
26. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas
27. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix
28. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas
29. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours
30. MDM-2 deregulation in breast carcinomas and sarcomas. [Abstract]
31. The p53-binding protein MDM-2 gene is differentially expressed in human breast carcinoma
32. Human ct-globin genes demonstrate autonomous developmental regulation in transgenic mice
33. A difference in the splicing patterns of the closely related normal and variant human growth hormone gene transcripts is determined by a minimal sequence divergence between two potential splice-acceptor sites
34. Chronic lymphocytic leukemia: Proposals for a revised prognostic staging system
35. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo